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Abstract 
Although recognized 25 years ago, the traditional serrated adenoma (TSA) remains an 
ongoing source of diagnostic and biological debate.  Recent research has greatly improved 
our understanding of the morphological and molecular aspects of these polyps.  In particular, 
the recognition of ectopic crypt foci (ECFs) in combination with typical cytology and slit-like 
serrations improves diagnostic reproducibility.  Awareness that many TSAs particularly, 
BRAF mutated TSAs, arise in precursor micro vesicular hyper plastic polyps (MVHPs) and 
sessile serrated adenomas (SSAs) can aid in making this diagnosis and should not be 
confused with an SSA with dysplasia (SSAD).  At a molecular level, TSAs can be divided 
into two groups based on their BRAF or KRAS mutation status.  The development of overt 
cytological dysplasia is accompanied by TP53 mutation, Wnt pathway activation and in some 
cases, silencing of CDKN2A.  Importantly, however, mismatch repair enzyme function is 
retained.   
Thus, the TSA is an important precursor of aggressive molecular subtypes of colorectal 
carcinoma. 
KEY WORDS: Serrated polyp, traditional serrated adenoma, CIMP, KRAS, BRAF. 
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Introduction and History 
In 1984, Urbanski and colleagues described an adenocarcinoma arising within an unusual 
colonic polyp [1].  This polyp was characterized by a “mixed  
morphology” of hyper plastic and adenomatous areas.  While not using the term “serrated 
polyp”, this perhaps is the first description of a polyp with a serrated luminal profile and 
harboring conventional adenomatous dysplasia  [1].  The authors of this paper described the 
serrated areas as: “papillary infolding, with cells exhibiting strong cytoplasmic eosinophilia, 
goblet cell dystrophy, and varying degrees of dysplasia” [1]. 
The traditional serrated adenoma (TSA) was first reported by Longacre and Fenoglio-Preiser 
in 1990 under the more generic label of serrated adenoma  [2].  They described a polyp with 
admixed features of hyperplastic polyp and conventional adenoma.  Many had a distinctive 
cytology, characterised by abundant eosinophilic cytoplasm and centrally placed, pencillate 
nuclei.  This polyp was subsequently confused with subsets of sessile serrated adenomas 
(SSA), sessile serrated adenomas with dysplasia (SSAD) and tubulovillous adenomas (TVA) 
with architectural serration. Much of the confusion was  
removed in 2003 when Torlakovic and Snover published their seminal paper describing the 
histological features of the SSA [3].  At the same time they designated the original ‘serrated 
adenoma’ as the traditional serrated adenoma to better separate it from the newly described 
SSA.  Subsequently, they have  
addressed key diagnostic features of the TSA, with a particular focus on the importance of 
ectopic crypt formations or foci (ECF) [4].  The 4th edition of the WHO Classification of 
Tumours of the Digestive Tract emphasizes protuberant and viliform growth and ECFs in the 
diagnosis, reflecting the findings of these important papers [5]. 
Our understanding of the molecular biology of TSAs has also continued to evolve. MAP 
kinase pathway activation is established as a critical early  
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(probably initiating) event and occurs by either activating BRAF or KRAS  
mutation [6-9].  The CpG island methylator phenotype (CIMP) then develops in a subset of 
TSAs as a direct result of these initial mutations [10,11].  Interrogation of the histological and 
molecular events that occur as these polyps progress towards carcinoma has been more 
limited, but a few recent papers have enhanced our understanding of this process [6,7,12]. 
In this review we aim to highlight advances in the clinicopathological and  
molecular understanding of the TSA that have occurred since the publication of the 4th 
edition of the WHO classification of tumors of the gastrointestinal tract [5] and to frame this in 
a manner helpful to the practicing pathologist.  In particular, we will address the issues of 
diagnostic features, precursor polyps, dysplasia in the context of a TSA and the molecular 
subtypes of carcinoma  
expected to arise from these lesions. 
 
Clinicopathological and endoscopic features 
Traditional serrated adenomas are rare polyps, comprising 0.56-1.9% of all colorectal polyps 
[2,13-16].  The mean size at diagnosis ranges from 9-14mm, there is no obvious gender 
predilection and they are mostly distal and protuberant [6-9,14,16].  The mean age at 
diagnosis tends to be in the sixth or seventh decade. The endoscopic appearances of the 
TSA have not been extensively investigated, but a pine-cone like appearance has been 
described [17].  Using magnification chromoendoscopy they have a fern-like or stellate pit 
pattern [18].  Macroscopically TSAs can be either sessile or protuberant [18].  Proximal cases 
are more likely to be sessile than distal lesions6. 
Due to their rarity, current surveillance guidelines for TSAs are based on limited evidence.  
At present the US multi society-task force on colorectal cancer recommends a three-year 
surveillance interval after a diagnosis of a TSA [19]. 
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Diagnostic criteria and guidelines – recent advances and distinction from other 
polyps 
There have been considerable recent advances in the histological diagnosis of the TSA (see 
Figure 1 for a morphologic comparison of serrated polyps and the diagnostic features of 
TSA).  In 2008, ECFs gained attention as a feature helpful to identify TSAs and to distinguish 
them from SSAs4.  ECFs are recognized as epithelial buds with their bases not anchored to 
seated on the muscularis mucosae and are found along the sides of the villous projections of 
the polyp (Fig 1G).  Some have regarded these ECFs are the proliferation zone of  TSAs, but 
the Ki-67 proliferation in these foci are not always high.  More recently, it has been 
recognized that a subset of TVAs also harbor ECFs [20,21].  In addition, some TSAs, in 
particular small polyps, do not show ECFs [6,8].  Several recent publications have re-
emphasized the striking similarity between the TSA and the normal small bowel epithelium 
as a critical component of the diagnosis [6,20-22].  In particular the characteristic cytological 
appearance of the TSA and the presence of a distinctive form of serration are very useful 
clues to making the diagnosis.  The typical cell of the TSA is one with plentiful, intensely 
eosinophilic cytoplasm and centrally placed, palisaded, penicillate nuclei.  These cells are so 
characteristic of the TSA that outside of the setting of the very rare goblet cell rich variant, it 
is very difficult to justify this diagnosis if they are not the predominant component.  
Conversely, although small patches of cells with these features can be seen frequently in 
other polyp types, it is very unusual to see a polyp comprised predominantly of these cells 
that does not qualify to be diagnosed as a TSA.  In tight association with this cytology are the 
characteristic epithelial serrations. These have been described variously as ‘slit-like’ or 
‘table-top’ but essentially describe the same feature [6,21].  Although the classic TSA 
cytology can be seen on its own, slit –like serrations essentially always accompany the 
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eosinophilic cells.  When seen together, the diagnosis of TSA must always be considered, 
regardless of the presence or absence of ECFs.  That being said, the vast majority of TSAs 
greater than 10mm in diameter will have all three features [6].  Although protuberant growth 
and distal location have been emphasized in the past, it is now becoming clear that sessile 
and proximal TSAs are relatively common. These TSAs are mostly BRAF mutated and have 
frequent origin in a precursor polyp, in particular microvesicular hyperplastic polyps (MVHP) 
and SSAs [6,8]. 
This concept of TSAs arising in MVHPs/SSAs is not new but remains,  
surprisingly controversial [4,23,24].  In our opinion this finding has now been so well 
documented by numerous groups that it should no longer be an issue of debate. In fact 30-
50% of TSAs appear to arise in one of these precursors [6,8,9,22].  The relative proportions 
arising in MVHPs versus SSAs are somewhat variable and likely reflects differences in 
diagnostic criteria.  Groups that use the single crypt criteria for the diagnosis of a SSA are 
likely to have higher proportions of SSA than other groups [13,25].  More important in this 
context is recognition of the TSA component (as this will dictate the surveillance interval) and 
separating this process from dysplasia arising in an SSA. This issue will be discussed further 
in a subsequent section.  
The final morphological point of discussion relates to the controversial concept of dysplasia 
in the TSA.  Many (probably most) pathologists consider the TSA to be inherently dysplastic 
and routinely report low-grade dysplasia in TSAs mainly on the basis of elongated, 
penicillate nuclei. We propose an alternate view, utilizing the same schema as is accepted 
for the SSA and SSAD.  In our view, while the ordinary TSA is undoubtedly neoplastic, it 
does not have inherent cytological dysplasia.  The eosinophilic cells of an ordinary TSA are 
not overtly atypical, do not show mitoses, have minimal proliferative activity by Ki-67 staining 
and do not show other immunohistochemical changes to suggest dysplasia (i.e. no abnormal 
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staining with β-catenin, p53 and p16) [6,7,12].  However, subsets of TSAs do develop areas 
of definite adenomatous or conventional cytological dysplasia reminiscent of adenomatous 
polyps [6-9,12].  The proportions with overt dysplasia vary in different series, but after 
considering selection bias in the published literature, a figure of 10-20% is probably reflective 
of the incidence of adenomatous dysplasia in TSA.  Similar to SSAs this is typically 
recognized as an abrupt transition from the adjacent ordinary TSA.  In our experience, the 
pattern is usually serrated, being characterized by cells with abundant eosinophilic 
cytoplasm, basally located vesicular nuclei and frequent, often atypical, mitoses.  This true 
“serrated” dysplasia is much different to the bland eosinophilic cells typical of the TSA. 
Although less common, conventional adenomatous dysplasia can also occur in these polyps.  
Tsai et al, reported serrated dysplasia predominantly in BRAF mutated TSAs and 
conventional dysplasia occurring in KRAS mutated TSAs [12].  However, this dichotomy was 
not seen in recent series [6].  Regardless, the major issue for the practicing pathologist is to 
recognize areas of overt (serrated or adenomatous) dysplasia arising in a TSA and to bring 
this to the attention of the endoscopist.  We do not feel, at this juncture, that there is any 
merit in separating or reporting serrated dysplasia from adenomatous dysplasia.  This will 
sow confusion and not enough is known about the biology and natural history of these two 
forms of dysplasia.  For the moment, it is perhaps prudent to merely “lump” the two into just 
dysplasia accompanying a TSA.  Although specific surveillance guidelines for this scenario 
have not been developed, it may be prudent to follow these patients closely.  There is a 
slight difference of opinion whether the grade of dysplasia accompanying a TSA is 
mentioned or not.  Practice is dictated by personal preference and regional guidelines.  In 
some countries only high-grade dysplasia, if present, is reported.  If high-grade dysplasia is 
mentioned in the pathology report, it may serve as a flag for more vigilant clinical 
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surveillance.  The reporting of low-grade dysplasia is probably not necessary.  The molecular 
changes that occur in these areas of overt cytological dysplasia will be discussed in detail in 
a following section, but provide further support to the concept of a non-dysplastic – 
dysplastic – carcinoma sequence in the TSA.  “Ordinary” or usual TSAs (i.e. those without a 
discrete area of dysplasia) are designated as such with no mention of dysplasia.  When 
discrete dysplasia is present it is regarded as TSA with dysplasia (TSAD) and a comment 
that these are polyps of an advanced nature and close surveillance may be prudent. 
 
Differential Diagnosis 
See Figure 1 and Table 1.  The polyps that create the most confusion with TSAs are the 
SSA and a subset of TVAs with ECFs. In our opinion the latter polyps create the most 
problems [21].  This is very likely because these TVAs share many of the features of TSAs, 
namely they tend to be large, protuberant polyps with ECFs.  Furthermore, they may also 
show filiform change, a feature typically associated with TSAs but that can be seen in large 
polyps of any type, even outside of the large bowel [20,26,27].  In contrast to TSAs, these 
TVAs do not show extensive eosinophilic cells and essentially never have the slit-like pattern 
of epithelial serration [21].  In the event of two distinct components (TVA and TSA) coexisting 
in the same polyp, these “mixed” polyps may justifiably be labelled as a TVA with TSA areas 
or vice versa.  
SSAs can sometimes be confused with TSA.  This is unsurprising given that TSA arising 
within a pre-existing MVHP/SSA displays a morphological spectrum.  It is not unusual to see 
small patches of eosinophilic cells in SSAs, but to us, this feature alone is insufficient to 
justify a diagnosis of TSA.  Importantly, we also do not consider this change to represent 
serrated dysplasia and hence justifying a diagnosis of SSAD. Instead, in routine practice we 
simply ignore this finding and leave the diagnosis as ordinary SSA.  We make a diagnosis of 
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TSA when two of the three features of eosinophilic cells, slit-like serrations and ECFs are 
seen.  This is most reliable in well-oriented sections, as the crypts of SSAs, when viewed in 
cross-section can appear similar to slit-like serrations. In addition, some SSAs harbor cells 
with abundant but palely eosinophilic cytoplasm, more in keeping with a gastric phenotype 
than the bright eosinophilia of a TSA.  
 
Molecular and Immunohistochemical Features 
See Figure 2.  The vast majority of TSAs are probably initiated by activating mutation of 
either BRAF or KRAS [6,8,9,12].  A small percentage of TSAs are wild-type for both of these 
genes, but they seem to segregate closely with the KRAS mutated group.  Recently it has 
been demonstrated that BRAF and KRAS mutations are independently capable of inducing 
CpG island methylation [10,11].  BRAF mutation status is strongly correlated with the CIMP-
high phenotype, whereas KRAS mutation tends to induce less extensive methylation. This is 
reflected in studies of TSAs showing that BRAF mutated TSAs are mostly CIMP-high, 
whereas KRAS mutated TSAs are more often CIMP-low [6].  It should be noted that different 
laboratories use different panels to define CIMP and this can make comparison between 
studies problematic [12,27-29].  Regardless, MAP kinase pathway activation and CIMP 
status appear to be determined relatively early in the development of the TSA, before the 
development of overt dysplasia. 
Immunohistochemically, ordinary TSAs have a reproducible pattern of staining.  In particular, 
CK20 staining is present in the eosinophilic cells and absent in the ECFs [4].  Ki67 shows the 
opposite pattern.  MUC2 and MUC5AC are usually  
widely expressed, whereas MUC6 is infrequently present. 
The development of overt cytological dysplasia is accompanied by additional molecular 
events. TP53 mutation, as demonstrated by strong p53 immunohistochemical staining, is the 
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most frequent event and is seen in over half of TSAs with dysplasia [6,7,12].  Wnt pathway 
activation, evidenced by a shift to nuclear β-catenin staining, is also frequently present 
[6,7,12].  In the context of colorectal carcinogenesis, most Wnt pathway activation is induced 
by loss of function mutations of the APC gene; however APC mutation is uncommon in 
serrated polyps. As such it is likely that methylation induced silencing of  
upstream Wnt suppressors activates the Wnt signaling pathway in these polyps.  Loss of 
staining for the critical tumor suppressor p16 protein, presumably reflecting methylation 
induced silencing of CDKN2A, occurs almost exclusively in BRAF mutated TSAs and 
appears to be a late event in malignant progression [6].  In  
contrast, KRAS mutated TSAs tend to show strong p16 staining in areas of  
dysplasia, presumably reflecting up-regulation of CDKN2A, in an attempt to block 
uncontrolled cell proliferation. 
Finally and perhaps most importantly, mismatch repair enzyme function is  
retained in essentially all TSAs regardless of BRAF or KRAS mutation  
status [5,6,12].  BRAF mutated, microsatellite stable colorectal carcinomas are known to be 
aggressive tumors with a poor prognosis [30,31].  As such the TSA may be an important 
precursor of these aggressive cancers.  Furthermore, it has recently been demonstrated that 
KRAS mutated carcinomas are also associated with a poor prognosis, meaning that 
essentially all cancers arising from TSAs are aggressive [32,33]. 
Although TSAs are thought to be rare, they are encountered, not infrequently, in centers with 
high gastrointestinal case volumes and an active  
gastroenterology/endoscopic service.  As such pathologists are likely to  
encounter more examples of TSA.  Awareness of the constellation of histologic features and 
variants will enable a correct diagnosis to be made.  Surgical pathologists should also be 
aware that overlap of histologic features occurs and not to label a polyp based on one 
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feature only.  In addition, transitions between TSA and other serrated polyps as well as 
conventional adenomas occur.  TSAs are important to recognize as they may flag a 
molecularly aggressive type of colorectal cancer.    
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LEGENDS TO FIGURE 
Figure 1 A-G: 
1A&B:  Hyperplastic polyp showing a semi-sessile lesion composed of serrated tubules with 
most prominent serration seen in the superficial or upper third of the crypt and surface 
(luminal tufting).  In 1B the base of the hyperplastic polyp can be appreciated as narrow, 
pointed with fewer goblet cells and lacking luminal serration.  
1C: Sessile serrated adenoma or polyp by contrast, has more goblet cells throughout the 
lesion, has basal dilation with bases often distended by mucin producing a club-shaped 
appearance.  In addition, other characteristic architectural features are evident: serrations 
present at the base of some crypts, boot-shaped crypts showing horizontal spread along the 
muscularis mucosae. 
1D: This is an example of a sessile serrated adenoma with high-grade dysplasia (SSAD).  
The dysplasia has the same cytologic features associated with adenomatous high-grade 
dysplasia: stratification of hyperchromatic, elongated, pleomorphic nuclei, and suprabasal 
mitoses.  In addition, there is architectural complexity (crowded, coalesced glands) to 
supplement the cytologic atypia.  The luminal serrated profile is retained and is an important 
feature separating SSAD from a conventional adenoma.  Another useful feature to look for is 
the presence of SSA without dysplasia admixed within such polyps; there is a usually a 
sharp transition from non-dysplastic to dysplastic areas.  Low-grade dysplasia within a SSA 
has less severe cytologic atypia and also retains luminal serration. 
1E-G: Traditional serrated adenoma (TSA) as opposed to hyperplastic and sessile 
serrated polyps is a more exophytic, villiform lesion.  The individual fronds or villi 
constituting the lesion are lined by tall columnar cells with deeply eosinophilic 
cytoplasm (although a goblet cell-rich variant with less eosinophilic cytoplasm has 
been described).  The luminal aspect has a very characteristic pattern of serration: 
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there are clefts creating flat-topped serrations rather than delicate saw-toothed tufts 
seen in hyperplastic and sessile serrated polyps.  In addition the luminal surface has 
a brush border reminiscent of small bowel mucosa.  The nuclei are elongated and 
penicillate, basal oriented and generally lacking stratification, pleomorphism and 
mitoses.  It is for this reason we feel that traditional serrated adenomas do not show 
inherent adenomatous dysplasia.  Like SSA with dysplasia, we believe that TSAs 
exist with and without adenomatous dysplasia.  Ectopic crypt foci (ECFs) are a 
hallmark (but not exclusive) feature of TSA (arrows).  They are encountered most 
readily and in the highest numbers in TSA.   
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Figure 2: 
This is a schematic representation of the currently known molecular alterations in sessile 
serrated adenomas with dysplasia (SSAD) and traditional serrated adenomas with dysplasia 
(TSAD). 
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Figure 2 
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Table 1: Comparison of Serrated polyps 
Polyp Location Endoscopy Cancer risk Molecular 
alteration 
Surveillance 
HP Mainly 
right 
sessile 
pale, star-
like pit 
pattern 
none/minimal Microvesicular 
HP BRAF 
<10mm: 5 
yrs 
SSA Mainly 
Right 
sessile, flat 
on crest of 
mucosal 
fold, mucus 
cap, cloud-
like surface 
1 with 
dysplasia: 
2x, 
>/=10mm: 3x 
BRAF 1;<10mm: 
5yrs 
>1;<10mm: 
3-5 yrs 1-3; 
>/= 10mm: 
3yrs 
TSA Mainly 
Left 
pine cone, 
fern like, 
Stellate pit 
pattern 
Yes BRAF and K-
ras 
every 3 yrs 
 
 
